China-based Allorion Therapeutics has entered into a licensing agreement with Avenzo Therapeutics Inc., granting the US firm global development and commercialization rights (excluding Greater China) to Allorion’s cyclin-dependent-kinases 2 (CDK2) inhibitor. The agreement also includes an exclusive option for a pre-clinical program anticipated for IND filing in 2025.
As part of the agreement, Avenzo will pay Allorion an upfront fee of USD 40 million and is committed to undisclosed milestone payments, along with tiered royalties based on sales. The potential total value of the deal, should Avenzo exercise its option for both programs, is reported to exceed USD 1 billion.
Allorion’s in-house developed ARTS-021 has demonstrated high kinase selectivity, favorable pharmacokinetic properties, and potential optimal preclinical efficacy in studies. The drug is currently undergoing a Phase I clinical study in the US for the treatment of HR+/HER2- metastatic breast cancer and other advanced solid tumors.- Flcube.com
